Phase 4 N=41 Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
Chronic Migraine
Primary: Numeric Rating Scale (NRS) — 3.18; 3.78; 2.53; 3.51 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=32 Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)
Transplant; Failure, Kidney
Primary: Percent Change in Mean Fluorescence Index (MFI) of Donor Specific Antibodies (DSA) With Increasing Doses of Enteric-Coated Mycophenolate Sodium (EC-MPS) — 43.1 percent…
Phase 3 N=112 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea
Rosacea
Primary: Composite Success Assessment (CEA) and Patient Self Assessment(PSA). — 32; 48; 33; 46 participants
Phase 2 N=38 Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 56 percentage of participants
Phase 2 N=43 Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Esophageal Cancer
Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants
Phase 3 N=844 Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
Opioid-Induced Constipation (OIC)
Primary: Incidence of Patients Experiencing at Least One Adverse Event (AE) — 437; 195 Participants
Phase 2 N=60 Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors
Substance Abuse · HIV Infections
Primary: Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12). — 40; 6 Percentage reduction
Phase 2 N=104 Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction
Nonmalignant Breast Conditions · Breast Cancer
Primary: Number of Subjects With Drain Bulb Fluid Bacterial Colonization at Approximately 1 Week — 10; 21 participants — p=0.02
Phase 2 N=191 Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma
Blunt Trauma · Penetrating Wound · Hemorrhagic Shock
Primary: Total Volume of All Crystalloid Given for Early Resuscitation (Feasibility) — 2.04; 1.04; 1 liters
Phase 3 N=392 Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
Asthma
Primary: FEV1 peak0-3 Change From Baseline — 0.438; 0.550; 0.528 litres — p=0.0457
N/A N=5,970 Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs
Colorectal Cancer
Primary: Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem…
Phase 4 N=59 Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain
Chest Pain Syndrome
Primary: Length of Hospital Stay — 7.63; 8.20 Hours — p=0.79
N/A N=232 The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
Schizophrenia · Schizoaffective Disorder · Major Depression
Primary: Family-Clinician Contact (Including Contact With FMPO Clinician) — .4; .3; 1.6; .3 Number of Interactions
Phase 3 N=80 Post Traumatic Stress Disorder (PTSD) Hyperarousal Symptoms Treated With Physiological Stress Management
Stress Disorders, Post-Traumatic
Primary: Change Scores for Criteria D Items on the CAPS Structured Clinical Interview — -1.20; -6.27 units on a scale — p=.27
N/A N=23 Treatment of Keratosis Pilaris With 810 nm Diode Laser
Keratosis Pilaris (KP)
Primary: Difference in Disease Severity Scores — 4; 3 units on a scale